Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Nature Reviews. Cancer|January 19, 2016
BRCAness revisitedChristopher J Lord, Alan Ashworth
BMC Biology|April 14, 2010
Biology-driven cancer drug development: back to the futureChristopher J Lord, Alan Ashworth
Current Opinion in Pharmacology|July 23, 2008
Targeted therapy for cancer using PARP inhibitorsChristopher J Lord, Alan Ashworth
Science (New York, N.Y.)|March 18, 2017
PARP inhibitors: Synthetic lethality in the clinicChristopher J Lord, Alan Ashworth
Nature Medicine|November 9, 2013
Mechanisms of resistance to therapies targeting BRCA-mutant cancersChristopher J Lord, Alan Ashworth
Nature|January 20, 2012
The DNA damage response and cancer therapyChristopher J Lord, Alan Ashworth
Nature Structural & Molecular Biology|June 6, 2007
RAD51, BRCA2 and DNA repair: a partial resolutionChristopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology|June 30, 2018
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?Alan Ashworth, Christopher J Lord
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Bringing DNA repair in tumors into focusChristopher J Lord, Alan Ashworth
Current Opinion in Genetics & Development|April 8, 2019
Dissecting PARP inhibitor resistance with functional genomicsStephen J Pettitt, Christopher J Lord
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Nature Reviews. Cancer|January 19, 2016
BRCAness revisitedChristopher J Lord, Alan Ashworth
BMC Biology|April 14, 2010
Biology-driven cancer drug development: back to the futureChristopher J Lord, Alan Ashworth
Current Opinion in Pharmacology|July 23, 2008
Targeted therapy for cancer using PARP inhibitorsChristopher J Lord, Alan Ashworth
Science (New York, N.Y.)|March 18, 2017
PARP inhibitors: Synthetic lethality in the clinicChristopher J Lord, Alan Ashworth
Nature Medicine|November 9, 2013
Mechanisms of resistance to therapies targeting BRCA-mutant cancersChristopher J Lord, Alan Ashworth
Nature|January 20, 2012
The DNA damage response and cancer therapyChristopher J Lord, Alan Ashworth
Nature Structural & Molecular Biology|June 6, 2007
RAD51, BRCA2 and DNA repair: a partial resolutionChristopher J Lord, Alan Ashworth
Nature Reviews. Clinical Oncology|June 30, 2018
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?Alan Ashworth, Christopher J Lord
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Bringing DNA repair in tumors into focusChristopher J Lord, Alan Ashworth
Current Opinion in Genetics & Development|April 8, 2019
Dissecting PARP inhibitor resistance with functional genomicsStephen J Pettitt, Christopher J Lord
Pageof 23